Asher Bio: Cis-Targeted Cancer Immunotherapy
Asher Biotherapeutics is pursuing a "cis-targeting" platform designed to selectively activate cancer-fighting immune cells without the systemic toxicity of traditional IL-2 — an ambitious scientific journey still in early-stage clinical trials.
Think & Rich